Menu
Menu
SOPHiA GENETICS is excited to attend this year’s Association of Molecular Pathology (AMP) Annual Meeting!
Find us at booth #921 to learn about how we are enabling breakthrough innovations in cancer research.
Check back soon for more information on our Corporate Workshop.
Lorem ipsum dolor sit amet tristique consequat aenean fusce tristique volutpat. Luctus sagittis hendrerit proin quam dictum netus feugiat semper pellentesque. Feugiat et porttitor nibh ac nisi lobortis porttitor mi proin nulla. Elementum egestas pretium quis praesent sagittis nunc maecenas risus facilisis augue scelerisque nisl integer venenatis. Orci tempus dui vel nisl justo aenean nec condimentum semper mi.
Tempor pharetra integer suspendisse consectetur sodales tristique nibh fermentum praesent. Fringilla venenatis fusce vivamus mauris ac duis eiusmod magna nulla aliqua turpis consectetur platea. Risus laoreet netus id egestas phasellus duis incididunt vivamus libero tellus sodales. Platea sodales lobortis rhoncus curabitur ornare orci nisl augue mi do. Maecenas curabitur condimentum erat mi donec porttitor bibendum congue iaculis vitae.
Tempor pharetra integer suspendisse consectetur sodales tristique nibh fermentum praesent. Fringilla venenatis fusce vivamus mauris ac duis eiusmod magna nulla aliqua turpis consectetur platea. Risus laoreet netus id egestas phasellus duis incididunt vivamus libero tellus sodales. Platea sodales lobortis rhoncus curabitur ornare orci nisl augue mi do. Maecenas curabitur condimentum erat mi donec porttitor bibendum congue iaculis vitae.
We are thrilled to be back at 15th World Clinical Biomarkers & Companion Diagnostics Summit. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
If you are attending, don’t miss our talk on Thursday, September 25th, from 11.00 to 11.30 am, in Track A.
Bridging the Gap: A Hybrid Deployment Model for Scaling Innovation in Oncology”
Jess Lambe, Vice President and Managing Director of BioPharma Business Development, SOPHiA GENETICS
Join us at ESMO Asia 2025! Learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform by leveraging our unique AI-powered expertise and comprehensive product offering. Discover how we uncover insights from complex oncology data, driving faster discovery of new stratifying biomarkers, in addition to aiding in the commercialization of precision medicines.
We are excited to announce our presence at the World Companion Diagnostics & Liquid Biopsy Summit APAC. Meet our BioPharma team to learn more about our liquid biopsy portfolio and how it supports BioPharma companies to address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
If you are around, don’t miss our Plenary talk, to discover how SOPHiA GENETICS is empowering Pharma companies to advance precision medicine with next-generation genomics solutions, enhancing worldwide patient access to innovative therapies
“Innovative Ways to Democratize Precision Medicine Testing”
Nicholas Tan, Managing Director APAC, SOPHiA GENETICS
We are glad to return to BioTechX Europe, in Basel. Join us at our booth and meet our BioPharma and Multimodal R&D experts to learn how we help BioPharma companies address challenges throughout the drug development continuum with data solutions tailored to their needs, bringing more effective drugs to the right patients.
We are glad to be at BioTechX USA 2025, where you will have the chance to meet our BioPharma and Multimodal R&D experts at our booth, for two days of exciting networking, innovation, and insights sharing on the potential of AI-driven solutions to transform precision medicine.
We’re thrilled to be back at International Congress of Pathology and Laboratory Medicine (ICPALM 2025)
Join SOPHiA GENETICS at Booth S26 as we showcase our latest breakthroughs in data-driven medicine. Discover how our advanced solutions are transforming clinical insights across Liquid Biopsy, Solid Tumors, Hematologic Malignancies, and more.
We look forward to connecting with you in person in Malaysia!
We are glad to return to Swiss Biotech Day 2025, where you will have the chance to meet our BioPharma and Medical teams for two days of exciting networking, innovation, and insights sharing on the potential of AI-driven solutions to transform precision medicine.
Join us on May 5th at 16:45 pm, in the Montreal room, for an engaging panel discussion on the transformative role of AI-powered technology in building scalable, high-performance healthcare solutions. Discover how collaboration drives innovation and advances precision medicine.
Harnessing AI & Big Data: The Next Frontier in Biotech and Healthcare
Moderator:
Panelists:
We are thrilled to announce our presence at the 3rd edition of Artificial Intelligence for Oncology. You will have the chance to meet our BioPharma and Multimodal R&D experts and learn how we help BioPharma companies address challenges throughout the drug development continuum with data solutions tailored to their needs, bringing more effective drugs to the right patients.
If you are attending, don’t miss our talk on Friday, May 9th at 3.25pm, during the Industry Symposium.
“Accelerating Precision Oncology with Multimodal Data Analytics”
Hamza Boulaala, Data Scientist, Multimodal R&D, SOPHiA GENETICS
Join us in this session to learn how SOPHiA DDM™ for Multimodal is transforming the future of oncology, one breakthrough at a time:
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.